keyword
MENU ▼
Read by QxMD icon Read
search

Castration resistant

keyword
https://www.readbyqxmd.com/read/29651807/editorial-comment-to-influence-of-prior-oral-ethinylestradiol-use-on-the-efficacy-of-enzalutamide-for-the-treatment-of-castration-resistant-prostate-cancer-in-men
#1
Kouji Izumi
No abstract text is available yet for this article.
April 12, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29651569/external-radiation-exposure-excretion-and-effective-half-life-in-177-lu-psma-targeted-therapies
#2
J Kurth, B J Krause, S M Schwarzenböck, L Stegger, M Schäfers, K Rahbar
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177 Lu-PSMA-617 (mean administered activity 6...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29650277/pharmacogenetics-of-androgen-signaling-in-prostate-cancer-focus-on-castration-resistance-and-predictive-biomarkers-of-response-to-treatment
#3
REVIEW
Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco, Andrea Sbrana, Erika Coppi, Luca Galli, Sergio Bracarda, Daniele Santini, Romano Danesi
Tumor heterogeneity strongly affects the molecular mechanisms driving resistance to hormonal therapies in castration-resistant prostate cancer. Since the current use of available treatments can be optimized on the basis of the molecular profile of tumor, the present review focuses on genetic biomarkers in prostate cancer and their application to a personalized treatment.
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#4
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644181/radium-223-for-metastatic-castration-resistant-prostate-cancer-results-and-remaining-open-issues-after-the-alsympca-trial
#5
EDITORIAL
Isabel Heidegger, Renate Pichler, Axel Heidenreich, Wolfgang Horninger, Andreas Pircher
No abstract text is available yet for this article.
March 2018: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29642359/re-cabazitaxel-versus-docetaxel-as-first-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-a-randomized-phase-iii-trial-firstana
#6
https://www.readbyqxmd.com/read/29630065/erratum-economic-burden-of-the-management-of-metastatic-castrate-resistant-prostate-cancer-in-italy-a-cost-of-illness-study-corrigendum
#7
(no author information available yet)
[This corrects the article on p. 789 in vol. 9, PMID: 29263702.].
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29629866/prognostic-and-predictive-clinical-factors-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#8
Daniel W Yokom, John Stewart, Nimira S Alimohamed, Eric Winquist, Scott Berry, Stacey Hubay, Jean-Baptiste Lattouf, Helene Leonard, Carla Girolametto, Fred Saad, Srikala S Sridhar
INTRODUCTION: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. METHODS: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29628317/syndecan-1-shedding-circulating-syndecan-1-is-associated-with-chemotherapy-resistance-in-castration-resistant-prostate-cancer
#9
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, Dávid Keresztes, Péter Nyirády, András Kubik, Miklós Romics, Ilona Kovalszky, Henning Reis, Boris Hadaschik, Shahrokh F Shariat, Gero Kramer
OBJECTIVES: Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to docetaxel. Therefore, prediction of docetaxel resistance has become of great clinical importance. Syndecan-1 (SDC1) has been currently shown to be involved in chemotherapy resistance in various malignancies including prostate cancer. The predicting value of serum SDC1 level has not been evaluated yet...
April 5, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29627197/time-to-event-outcomes-in-men-with-nonmetastatic-castrate-resistant-prostate-cancer-a-systematic-literature-review-and-pooling-of-individual-participant-data
#10
REVIEW
Markus Aly, Mahmoud Hashim, Bart Heeg, Johan Liwing, Amy Leval, Maneesha Mehra, Joe Lawson, Sabine D Brookman-May, Olof Akre
CONTEXT: Until recently, there has been a lack of evidence-based treatment alternatives in men with nonmetastatic castrate-resistant prostate cancer (NM-CRPC). However, new evidence-based treatment alternatives are emerging. OBJECTIVE: We aimed to describe time-to-event outcomes in NM-CRPC patients based on evidence from both prospective and retrospective studies. Second, we aimed to describe predictors of these outcomes in the same patient population. EVIDENCE ACQUISITION: A systematic review was conducted to identify clinical studies (both prospective and retrospective) in NM-CRPC patients...
April 4, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29626324/apalutamide-first-global-approval
#11
Zaina T Al-Salama
Apalutamide (ErleadaTM ) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. In February 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC). Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochemically-relapsed PC...
April 6, 2018: Drugs
https://www.readbyqxmd.com/read/29626121/reproducibility-and-repeatability-of-semi-quantitative-18-f-fluorodihydrotestosterone-fdht-uptake-metrics-in-castration-resistant-prostate-cancer-metastases-a-prospective-multi-center-study
#12
Hebert Alberto Vargas, Gem M Kramer, Andrew M Scott, Andrew Weickhardt, Andreas A Meier, Nicole Parada, Bradley J Beattie, John L Humm, Kevin D Staton, Pat B Zanzonico, Serge K Lyashchenko, Jason S Lewis, Maqsood Yaqub, Ramon E Sosa, Alfons J van den Eertwegh, Ian D Davis, Uwe Ackermann, Kunthi Pathmaraj, Robert C Schuit, Albert D Windhorst, Sue Chua, Wolfgang A Weber, Steven M Larson, Howard I Scher, Adriaan A Lammertsma, Otto Hoekstra, Michael J Morris
18 F-fluorodihydrotestosterone (18 F-FDHT) is a radiolabeled analogue of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer (mCRPC). Methods: We conducted a prospective multi-institutional study of mCRPC patients undergoing two (test/re-test)18 F-FDHT PET/CT scans on two consecutive days...
April 6, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29625534/burden-of-illness-of-chemotherapy-in-castration-resistant-prostate-cancer-patients-in-japan-a-retrospective-database-analysis
#13
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka, Kentaro Enjo
OBJECTIVE: The objective was to assess the burden of chemotherapy for castration resistant prostate cancer (CRPC) in Japan. METHODS: Utilizing a large administrative hospital data base we compared a set of outcome measures twelve months before and after initiation of chemotherapy, namely total medical costs, number of outpatient visits, number of hospital admissions, and number of days spent in hospital. RESULTS: A total of 598 CRPC patients were identified in the database...
April 6, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29623850/treatment-of-metastatic-castration-resistant-docetaxel-resistant-prostate-cancer-a-systematic-review-of-literature-with-a-network-meta-analysis-of-randomized-clinical-trials
#14
Davide Tassinari, Chiara Cherubini, Britt Roudnas, Emiliano Tamburini, Fabrizio Drudi, Emanuela Bianchi, Manuela Fantini, Francesco Montanari, Sergio Sartori
INTRODUCTION: To compare the efficacy of abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer. METHODS: An indirect comparison of overall survival (OS) and time to PSA progression among abiraterone acetate, enzalutamide, cabazitaxel and Radium-223 was performed with a network meta-analysis. OS in the entire population of patients was the primary end point. OS in ECOG 0-1/2, BPI-SF≤4/>4, pretreated with 1 or 2 courses of chemotherapy, age≤65/>65 patients, patients with only bone metastases or bone and visceral metastases, and time to PSA progression were the secondary end points...
April 4, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29616555/improvement-in-therapeutic-efficacy-and-reduction-in-cellular-toxicity-introduction-of-a-novel-anti-psma-conjugated-hybrid-antiandrogen-nanoparticle
#15
Chellappagounder Thangavel, Maryna Perepelyuk, Ettickan Boopathi, Yi Liu, Steven Polischak, Deepak A Deshpande, Khadija Rafiq, Adam P Dicker, Karen E Knudsen, Sunday A Shoyele, Robert B Den
Second generation antiandrogens have improved overall survival for men with metastatic castrate resistant prostate cancer; however, the antiandrogens result in suppression of androgen receptor (AR) activity in all tissues resulting in dose limiting toxicity. We sought to overcome this limitation through encapsulation in a prostate specific membrane antigen (PSMA)-conjugated nanoparticle. We designed and characterized a novel nanoparticle containing an antiandrogen, enzalutamide. Selectivity and enhanced efficacy was achieved through coating the particle with PSMA...
April 4, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29616091/molecular-and-cellular-mechanisms-of-castration-resistant-prostate-cancer
#16
REVIEW
Yiqiao Huang, Xianhan Jiang, Xue Liang, Ganggang Jiang
With increases in the mortality rate and number of patients with prostate cancer (PCa), PCa, particularly the advanced and metastatic disease, has been the focus of a number of studies globally. Over the past seven decades, androgen deprivation therapy has been the primary therapeutic option for patients with advanced PCa; however, the majority of patients developed a poor prognosis stage of castration resistant prostate cancer (CRPC), which eventually led to mortality. Due to CRPC being incurable, laboratory investigations and clinical studies focusing on CRPC have been conducted worldwide...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29615462/cell-free-dna-modification-dynamics-in-abiraterone-acetate-treated-prostate-cancer-patients
#17
Juozas Gordevičius, Algimantas Kriščiūnas, Daniel E Groot, Steven M Yip, Miki Susic, Andrew Kwan, Rafal Kustra, Anthony M Joshua, Kim N Chi, Art Petronis, Gabriel Oh
PURPOSE: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20-40% of patients. We aim to identify predictive biomarkers for AA-treatment response and understand the mechanisms related to treatment resistance. EXPERIMENTAL DESIGN: We used the Infinium Human Methylation 450K BeadChip to monitor modification profiles of cell-free circulating DNA (cfDNA) in 108 plasma samples collected from 33 AA-treated patients...
April 3, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29614830/role-of-stromal-paracrine-signals-in-proliferative-diseases-of-the-aging-human-prostate
#18
REVIEW
Kenichiro Ishii, Sanai Takahashi, Yoshiki Sugimura, Masatoshi Watanabe
Androgens are essential for the development, differentiation, growth, and function of the prostate through epithelial-stromal interactions. However, androgen concentrations in the hypertrophic human prostate decrease significantly with age, suggesting an inverse correlation between androgen levels and proliferative diseases of the aging prostate. In elderly males, age- and/or androgen-related stromal remodeling is spontaneously induced, i.e., increased fibroblast and myofibroblast numbers, but decreased smooth muscle cell numbers in the prostatic stroma...
April 2, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29610962/are-clinical-guidelines-designed-according-to-guidelines-cross-sectional-assessment-of-quality-and-transparency-of-clinical-guidelines-in-urology
#19
Roderick C N van den Bergh, Piet Ost, Christian Surcel, Massimo Valerio, Jurgen J Fütterer, Giorgio Gandaglia, Prasanna Sooriakumaran, Derya Tilki, Igor Tsaur, Guillaume Ploussard
PURPOSE: Guidelines and recommendations become increasingly important in clinical urologic practice. This study aims to inform clinicians using guidelines on how to evaluate the quality of the methodology and transparency of these documents. METHODS: The guidelines on management of castration-resistant prostate cancer of the American Urology Association, European Association of Urology, National Comprehensive Cancer Network, National Institute for Health and Care Excellence, European Society of Medical Oncology were reviewed using the AGREE-II tool (Appraisal of Guidelines for Research and Evaluation)...
April 2, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29610288/plasma-dna-and-metastatic-castration-resistant-prostate-cancer-the-odyssey-to-a-clinical-biomarker-test
#20
Anuradha Jayaram, Daniel Wetterskog, Gerhardt Attard
<b/> Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392-4. ©2018 AACR. See related article by Annala et al., p. 444 .
April 2018: Cancer Discovery
keyword
keyword
64694
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"